Home | Find A Doctor | Contact Us

 

A Phase 1b/2 Study Of Docetaxel And Prednisone, With Or Without ISIS 183750 (an eIF4E Inhibitor), In Patients With Castrate-Resistant Prostate Cancer


Principal Investigator: Seth Cohen, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
ISIS 183750 is an experimental drug, which has not been approved by the Food and Drug Administration. After it is tested in animals, an experimental drug, such as ISIS 183750, has to be tested to see if it works in people. It is not known if ISIS 183750 will be beneficial to you or anyone else. ISIS 183750 is designed to reduce the amount of a specific protein (eukaryotic translation initiation factor 4E; eIF4E) that your body produces, which might contribute to prostate cancer.  The purpose of this research study is to see if reducing the amount of eIF4E that your body produces will improve your prostate cancer or delay its worsening.  The purpose of Part 2 of the study is to see how well ISIS 183750 treats your prostate cancer when given in combination with docetaxel, a drug that is approved by the national health authorities for treating patient with prostate cancer.


Eligibility and Treatment Plan:

  • Male of at least 18 years old
  • Prostate cancer that has come back or gotten worse after medical or surgical castration
  • Cannot have a medical condition associated with active bleeding or are using anticoagulants (blood thinners)
  • Do not have another type of cancer
  • Is not being treated with other cancer drugs
  • Have not had specific cancer treatments in the past

Please call for more information.

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System